These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Dean CE Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):174-89. PubMed ID: 16376473 [TBL] [Abstract][Full Text] [Related]
83. [Quotidien prescription: between references and reality]. Verdoux H Encephale; 2006 Jan; 32 Pt 2():S10-1. PubMed ID: 16800079 [No Abstract] [Full Text] [Related]
84. Wayne Fenton's impact on academic neuroscience. Geyer MA; Tamminga CA Schizophr Bull; 2007 Sep; 33(5):1156-9. PubMed ID: 17617663 [TBL] [Abstract][Full Text] [Related]
85. Improving outcomes for patients with schizophrenia: new hope for an old illness. Seeman MV CMAJ; 1999 Mar; 160(6):826-8. PubMed ID: 10189430 [No Abstract] [Full Text] [Related]
86. Early detection and intervention in schizophrenia. Linszen DH; Dingemans PM; Lenior ME; Scholte WF; de Haan L; Goldstein MJ Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S31-4. PubMed ID: 9690968 [TBL] [Abstract][Full Text] [Related]
87. Maintenance therapy in schizophrenia. Marder SR Curr Psychiatr Ther; 1983; 22():141-50. PubMed ID: 6145546 [No Abstract] [Full Text] [Related]
88. Relapse prevention in schizophrenia - new therapeutic challenges. Kucukalić A; Dzubur-Kulenović A; Mehmedika-Suljić E Psychiatr Danub; 2007 Dec; 19(4):362-6. PubMed ID: 18000490 [TBL] [Abstract][Full Text] [Related]
89. [Priority for atypical antipsychotic drugs? Current studies clarify the issues]. Dose M Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252 [No Abstract] [Full Text] [Related]
90. [Long term drug treatments of schizophrenia]. des Lauriers A; Allilaire JF Rev Prat; 1980 Jan; 30(1):39-46. PubMed ID: 6103572 [No Abstract] [Full Text] [Related]
91. Quantifying clinical relevance in the treatment of schizophrenia. Correll CU; Kishimoto T; Nielsen J; Kane JM Clin Ther; 2011 Dec; 33(12):B16-39. PubMed ID: 22177377 [TBL] [Abstract][Full Text] [Related]
92. Important issues in the drug treatment of schizophrenia. Davis JM; Schaffer CB; Killian GA; Kinard C; Chan C Schizophr Bull; 1980; 6(1):70-87. PubMed ID: 6102795 [TBL] [Abstract][Full Text] [Related]
93. [Factors affecting the process of the recurrence of schizophrenia (a review)]. Davtian SE Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(3):115-20. PubMed ID: 1359721 [No Abstract] [Full Text] [Related]
94. Long-term neuroleptic treatment. Benefits and risks. Proceedings from a workshop, Copenhagen, 6th-7th September, 1979. Acta Psychiatr Scand Suppl; 1981; 291():1-159. PubMed ID: 6113728 [No Abstract] [Full Text] [Related]
96. Anti-inflammatory signaling in schizophrenia. Meyer U Brain Behav Immun; 2011 Nov; 25(8):1507-18. PubMed ID: 21664451 [TBL] [Abstract][Full Text] [Related]
97. Impact of antipsychotic treatment on long-term course of schizophrenic illness: an introduction. Tandon R J Psychiatr Res; 1998; 32(3-4):119-20. PubMed ID: 9793864 [No Abstract] [Full Text] [Related]
98. Rationale for emphasis on management over treatment of schizophrenia in clinical practice. Ahmed M; Osser DN; Boisvert CM; Albert LG; Aslam M Ann Pharmacother; 2007 Apr; 41(4):693-5. PubMed ID: 17389665 [TBL] [Abstract][Full Text] [Related]
99. Prodromal schizophrenia and atypical antipsychotic treatment. Kablinger AS; Freeman AM J Nerv Ment Dis; 2000 Oct; 188(10):642-52. PubMed ID: 11048813 [TBL] [Abstract][Full Text] [Related]
100. [Kinematic movement analyses and their application in psychiatry]. Juckel G; Mergl R; Hegerl U Psychiatr Prax; 2005 Apr; 32 Suppl 1():S31-7. PubMed ID: 15818518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]